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Abstract 27 
 28 
Background: PUFAs from fish oil appear to have anti-inflammatory and anti-oxidative effects and 29 
improve nutritional status in cancer patients.  30 
Objective: the aim of the study was to investigate the effect of eicosapentaenoic acid (EPA) plus 31 
docosahexaenoic acid (DHA), on inflammatory condition, oxidative and nutritional status in 32 
patients with lung cancer. 33 
Design: in our multicentre, randomised, double blind trial, 33 patients with a diagnosis of advanced 34 
inoperable non small cell lung cancer and undergoing chemotherapy were divided into two groups, 35 
receiving 4 capsules/day containing 510 mg of EPA and 340 mg of DHA, or 850 mg of placebo, for 36 
66 days. At the start of chemotherapy (T0), after 8 days (T1), 22 days (T2), and 66 days (T3), 37 
biochemical (inflammatory and oxidative status parameters) and anthropometric parameters were 38 
measured in both groups. 39 
Results: a significant increase of body weight in the n-3 group at T3 versus T0 was observed. 40 
Concerning inflammation, C-reactive protein and IL-6 levels differed significantly between the n-3 41 
and placebo groups at T3, and progressively decreased during chemotherapy in the n-3 group, 42 
evidencing n-3 PUFAs’ anti-inflammatory action. Concerning oxidative status, plasma reactive 43 
oxygen species levels increased in the placebo group versus the n-3 group at the later treatment 44 
times. Hydroxynonenal levels increased in the placebo group during the study, while they stabilized 45 
in the n-3 group. 46 
Conclusions: our data confirm that the continual assumption of EPA plus DHA determined an anti-47 
inflammatory and anti-oxidative action which could be considered a preliminary goal in anti-48 
cachectic therapy. 49 
50 
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Introduction 51 
 52 
The role of fish-oil supplementation in numerous diseases has been emphasised; these include 53 
coronary disease, rheumatoid arthritis, inflammatory diseases, and cancer (1, 2, 3, 4, 5, 6). 54 
Fish-oil supplementation has also been proposed for the treatment of cancer cachexia syndrome, an 55 
altered metabolic state characterized by anorexia, weight loss, asthenia, anaemia and alterations in 56 
carbohydrate, lipid and protein metabolism (7, 8). This syndrome is the major cause of morbidity 57 
and mortality in patients with advanced cancer (9). 58 
Previous studies using conventional nutrition have shown that it is impossible to increase the lean 59 
tissue in cachexia patients (10); therefore it is important to use natural substances possessing both 60 
nutritional and anti-cachectic properties (11). In particular, eicosapentaenoic acid (EPA), an n-3 61 
PUFA present in large amounts in fish oil, can be considered as a potential natural support: it has 62 
been shown to have anti-inflammatory properties, down-regulating both pro-inflammatory cytokine 63 
production and the acute-phase protein response in cancer patients (12, 13, 14). Pro-inflammatory 64 
cytokines, IL-1, IL-6, and TNF-α, are recognized to play a central role in the pathogenesis of 65 
cancer-related cachexia (15, 16). Furthermore, EPA has also been shown to inhibit activation of the 66 
ubiquitin proteasome pathway, by the proteolysis-including factor, a cachectic factor produced by 67 
cancer tissue, which induces atrophy of skeletal muscle in animal models (9). 68 
In 2006 (17) the administration of a dose of 2 g or 4 g of EPA was compared to placebo in 518 69 
cancer patients (gastrointestinal and lung), over an 8-weeks period. The results indicated that there 70 
was no benefit with the 4 g dose, but a potentially clinically relevant treatment effect with 2 g EPA 71 
per day. 72 
In recent years, many studies have addressed this subject, but without reaching any conclusions 73 
concerning survival improvement and weight increase. This failure might be attributed to sample 74 
heterogeneity, reduction of patient number at the end of studies, lack of patient compliance, or 75 
subclinical toxicity of the higher dose of EPA (18). 76 
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The Cochrane analysis published in 2009 (19) concluded that there was insufficient evidence to 77 
draw any conclusions about EPA supplementation in cancer patients with cachexia. This systematic 78 
review also suggested there is little evidence of harm from using EPA, especially when combined 79 
with Megestrol Acetate. 80 
The anti-inflammatory properties of EPA might also be involved in reducing oxidative stress. The 81 
association between reactive oxygen species (ROS), carcinogenesis, and progression of lung cancer 82 
has been widely demonstrated. The high percentage of oxidants in cigarettes smoke contributes to 83 
smoking-associated carcinogenesis (20). Asbestos fibres alter DNA of lung cells, with increased 84 
cell proliferation (21), by changing the redox state of the cells. Several mechanisms are responsible 85 
for the development of oxidative stress in cancer patients: the altered energy metabolism caused by 86 
the impossibility of normal nutrition in patients with anorexia, nausea and vomiting results in a 87 
reduced availability of glucose, proteins and vitamins, leading to increased free radicals (22, 23, 88 
24). Furthermore, chronic non-specific activation of the immune system, with excessive production 89 
of inflammatory cytokines, is responsible for increased production of ROS (25). An additional 90 
mechanism leading to oxidative stress derives from the use of anti-neoplastic therapy: many 91 
chemotherapics, and in particular alkylating agents and cisplatin, determine an increasing of ROS 92 
(26). 93 
The aim of the present study was to investigate the effect of fish-oil components, namely EPA plus 94 
docosahexaenoic acid (DHA), versus placebo, on inflammatory condition, oxidative and nutritional 95 
status, in patients with lung cancer  96 
 97 
 98 
Experimental Methods and Participants 99 
 100 
Study design 101 
 5
The study was a multicentre, randomised, double-blind trial conducted between May 2007 and May 102 
2008. This study was conducted according to the guidelines laid down in the Declaration of 103 
Helsinki and all procedures involving patients were approved by the Scientific Ethics Committee of 104 
the City of Turin, Italy (research protocol n° Eudra-CT 2006-002978-21). Written informed consent 105 
was obtained from all patients. Patients were randomised at enrolment using a sequential series of 106 
numbered sealed envelopes containing computer-generated random assignments. A copy of the 107 
randomisation sequence was kept in a locked cabinet apart from the study personnel. Study 108 
products were packaged identically and were not distinguishable from one another. 109 
Participants were randomly divided into two groups: the placebo group and the n-3 group (Figure 110 
1). The first group was provided with a daily dose of four capsules containing 850 mg of placebo 111 
(olive oil), the second with a daily dose of four capsules containing 510 mg of EPA and 340 mg of 112 
DHA, for 66 days (the entire period of chemotherapy). 113 
Olive oil was selected as placebo because of evidence that ingestion of this oil was unlikely to 114 
change the fatty acid composition of either plasma or cellular phospholipids. Self-reported capsule 115 
intake was used to determine patient compliance. 116 
Participants visited the research unit four times: at baseline (T0), after 8 days (T1), 22 days (T2), and 117 
66 days (T3), at which times a blood sample was taken and measurements were made (Figure 1). T0  118 
coincided with the start of chemotherapy. 119 
 120 
Eligibility criteria 121 
Baseline characteristics of patients recruited into this study are shown in Table 1. 122 
Patients were recruited with a clinical diagnosis of advanced inoperable non small cell lung cancer, 123 
in the 18 to 70 year age range, and with 10% or less weight loss over the last three months, before 124 
the start the study. Patients received 3 courses of chemotherapy with Cisplatin and Gemcitabine to 125 
the following schedule: baseline (T0), after 8 days (T1), 22 days (T2), and after 66 days (T3). Life 126 
expectancy was two months or longer; Karnofsky Performance Status was 80 or higher. 127 
 6
 128 
Exclusion criteria 129 
Patients were excluded if they had undergone chemotherapy failure, if metastases were present, if 130 
they were diabetic, had cardiovascular or infectious diseases, previous cancer (less than 5 years 131 
before or with relapse signs) or inflammatory disease. Patients with neurological deficiency or 132 
psychiatric diseases were also excluded. 133 
 134 
Nutritional status and dietary intake  135 
Patients were weighed on spring balance scales (Tanita Solar Powered Scale) without shoes and 136 
wearing light clothing. BMI was calculated as the ratio of body weight to the square of their height 137 
(kg/m2) (27). 138 
In our study we didn’t measure lean body mass with bioelectrical impedance analyser. 139 
At the start of the study, pre-illness weight, unintentional weight loss over the last 6 months, and 140 
height were recorded. 141 
Both group received the same dietary counselling with the aim to increase their energy and protein 142 
intake. A three day dietary recall was performed prior to assessment at baseline (week 0), and each 143 
week in the period of 66 days to assess the patients’ dietary intakes. Patients completed a dietary 144 
diary, and were instructed by a dietician how fill them out correctly. Data on food intake reported 145 
by dietary diaries were then translated into energy and protein intakes by means of specific tables 146 
validated for Italian foods (28). Patients were also requested to record the number of capsules of n-3 147 
fatty acids or olive oil supplement taken each day. 148 
 149 
Blood analysis 150 
Plasma and erythrocytes were obtained by centrifuging venous blood (collected in tubes containing 151 
EDTA and kept on ice until separation) at 3000xg for 5 min at 4°C (centrifuge J6M, Beckman, Palo 152 
Alto, CA, USA), and stored at -80°C until use. The percentage content of different fatty acids was 153 
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determined in the total lipids extracted from plasma, and in phospholipids (PLs) extracted from 154 
erythrocytes membranes (29). 155 
Albumin was analyzed by an autoanalyzer, whereas prealbumin (TBPA) and transferrin were 156 
detected quantitatively by immunoturbidity assay. C-reactive protein (CPR), IL-6, TNFα and PGE2 157 
production were evaluated in plasma by the ELISA method (R&D systems, Minneapolis, MN, 158 
USA). The levels of reactive oxygen species (ROS) were detected in the plasma using the probe 159 
2’,7’-dichlorofluorescin diacetate (DCFH-DA) and measured fluorimetrically (30). 160 
Hydroxynonenal (HNE) concentration was determined on plasma by the method of EsterBauer et 161 
al. (31). 162 
 163 
Statistical Analysis 164 
Results are expressed as means ± S.D. Significant differences between patients in the n-3 and 165 
placebo groups were assessed by the unpaired T test, whereas significant differences within groups 166 
were assessed by the paired T test, all tests being two-sided. Statistical analyses were performed 167 
using the statistical software package SPSS for Windows Version 17.0 (SPSS, Chicago, Illinois, 168 
USA) at baseline (T0), after 8 days (T1), 22 days (T2), and 66 days (T3). 169 
 170 
 171 
Results 172 
 173 
The series comprised 33 participants between 46 and 70 years old; they were randomly assigned to 174 
the placebo or the n-3 group. Baseline characteristics (T0) of patients are shown in Table 1. 175 
Fourteen participants, aged 50-70 years (mean age 60.57 ± 7.43 years), were allocated to the 176 
placebo group; 19 participants, aged 46-69 years (mean age 58.10 ± 6.72 years), were allocated to 177 
the n-3 group; 6 patients in the n-3 group (6 of 19: 31%) dropped out during the double-blind phase 178 
(2 patients changed department oncology, 2 refused treatment, 2 had diarrhea with capsules) Thus 179 
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13 participants in the n-3 group, (age 46-66 years; mean 55.56 ± 7.35 years) completed the study 180 
(Figure 1). 181 
 182 
Nutritional Status 183 
The patients’ nutritional status was not severely compromised, partly because some patients were 184 
overweight at the start of chemotherapy. Mean weight of the n-3 group was 75.10 kg (± 16.12) at 185 
baseline and 78.50 kg (± 15.94) at T3: an increase of 3.4 kg occurred, which was statistically 186 
significant (Figure 2). In the placebo group there was no increase: mean weight was 68.00 kg (± 187 
12.85) at baseline and 68.92 (± 13.44) at T3 (Figure 2). There was no statistical significance 188 
between the two groups at T3. 189 
Both groups had a satisfying calorie intake (1.02 g/kg in n-3 group and 0.93 g/kg in placebo group) 190 
but they took a different amount of proteins daily. Data for BMI and dietary intake (calories and 191 
proteins) revealed no statistically significant differences between the two groups. There was a non-192 
significant increase in daily calorie and protein intake in the n-3 group (Table 1).  193 
Nutritional blood parameters such as albumin, TBPA and transferrin did not differ between the two 194 
groups (data not shown). 195 
 196 
Percentage content of n-3 fatty acids in plasma and erythrocytes  197 
The percentage content of EPA in total lipids from plasma and in PLs from erythrocyte membranes 198 
is reported in Figure 3, which shows that EPA increased significantly in both plasma (panel A) and 199 
erythrocyte membranes (panel B) for the n-3 group, compared to the placebo group, at the two later 200 
experimental times. 201 
No significant difference was evident in the percentage content of EPA in the placebo group at any 202 
of the experimental times, for either plasma or erythrocytes, whereas in the n-3 group there was a 203 
significant increase in EPA between the T1 and T0, T2 and T0, T3 and T0, confirming the 204 
consumption of supplementary capsules. 205 
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The percentage content of DHA, in total lipids from plasma and in PLs from erythrocyte 206 
membranes, is reported in Figure 3 (panels C and D), which shows that DHA increased 207 
significantly in the plasma (panel C), but not in the erythrocyte membranes (panel D) for the n-3 208 
group, compared to the placebo group. Considering the percentage content of DHA in the placebo 209 
group throughout the experimental time, no variation was evident for either plasma or erythrocytes, 210 
whereas in the n-3 group, significant variations were detected, only for the plasma, between the T1 211 
and T0, T2 and T0, T3 and T0. 212 
The percentage content of docosapentaenoic acid (DPA), which is an intermediate between the EPA 213 
and DHA, was also measured, showing no significant change in the plasma and in the erythrocyte 214 
membranes from placebo and n-3 groups at all experimental times. 215 
 216 
Inflammatory parameters 217 
Figure 4 shows the trends of CPR, IL-6, TNF-α, and PGE2. In the n-3 group, CPR was not 218 
significantly changed between T0 and T3 (from 12.89 mg/l to 10.09 mg/l), while in the placebo 219 
group the increase, from 11.50 mg/l at T0 to 27.09 mg/l at T3, was significant. Comparing the two 220 
groups at T3, the difference was statistically significant (Figure 4, panel A). 221 
IL-6 values decreased at T3 from their T0 values in the n-3 group, and increased in the placebo 222 
group. Comparing the two groups at T3, the difference was statistically significant (Figure 4, panel 223 
B). TNF-α were higher in the placebo group than in the n-3 group, although not significantly so, 224 
possibly due to subject variability (Figure 4, panel C). Since n-3 PUFAs are able to inhibit the 225 
production of pro-inflammatory PGE2, this prostaglandin was evaluated in the plasma, using the 226 
ELISA test. A significant decrease in the n-3 group occurred during treatment, but no variation in 227 
the placebo group (Figure 4, panel D). 228 
 229 
Oxidative status 230 
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Since n-3 PUFAs could be damaged by ROS with the production of HNE, both HNE (panel A) and 231 
ROS (panel B) were evaluated in the plasma (Figure 5). Both these parameters increased at the later 232 
experimental times in the placebo group, whereas they decreased in the n-3 group. The HNE 233 
decrease in the n-3 group was statistically significant between T0 and T3, and the difference between 234 
the two groups was statistically significant at T3. ROS values were significantly less in n-3 group 235 
than in the placebo group,  at the latter two experimental times. 236 
 237 
 238 
Discussion 239 
 240 
Several studies (32, 33, 34) have emphasized that conventional nutritional support can only partially 241 
stop lean mass reduction in cancer patients: it is only possible to increase muscular mass by 242 
resolving metabolic alterations (35). Nutritional support is often wasted due to the hyper-metabolic 243 
state of the inflammatory pattern, and for this reason, in cancer patients, the first target of nutritional 244 
therapy should be to reduce the inflammatory state; n-3 PUFAs could have this effect (36, 37). For 245 
this reason, our study looked at the effect of n-3 PUFA administration in patients with advanced 246 
lung cancer, in order to evidence the ability of these compounds to improve patients’ nutritional 247 
status and reduce the inflammatory and oxidative pattern. In this trial, EPA and DHA, two PUFAs 248 
present in fish oil, were administered in combination, rather than EPA alone, as in most studies. 249 
Administration was in capsules rather than supplements, as occurred in Fearons’ trials (9, 17), and 250 
adherence to the study protocol was observed more closely. Detailed, consistent and persistent 251 
dietetic counselling, with assessment of any disorders connected with capsule assumption 252 
throughout the study, helped to obtain good compliance with the therapy and with the nutritional 253 
intake. Patients’ observance of dietetic recommendations was confirmed by the increase, in the 254 
plasma of the n-3 group, of EPA and DHA percentage contents from T0 to T3, compared with the 255 
placebo group. Changes in DHA content were not due to variation on DPA percentage content, 256 
 11
since the percentage content of this fatty acid did not show significant differences in all 257 
experimental times and in both groups. 258 
The patients did not take other dietetic supplements unless n-3 fatty acids or olive oil capsules. 259 
In regard to the nutritional status, we evidenced a slight increase, although not significant, of daily 260 
calorie and protein intakes during the study in the n-3 group, from start to end of chemotherapy, 261 
while calorie and protein intakes stabilized in the placebo group.  262 
The difference between two groups are random, in fact already the n-3 fatty acid group at T0 took 263 
more calories and this trend continued throughout the time. Moreover, a statistically significant 264 
increase in body weight was achieved in the n-3 group at T3 versus T0. It is not feasible that the 265 
slight increase of daily calorie and protein intakes may influence the variation in body weight. 266 
These data are particularly interesting compared to reports in the literature, which are not always 267 
univocal on this point: some studies (9, 10, 38, 39) that have examined the effect of fish oil in 268 
cachectic patients expressed the opinion that valid conclusions are difficult to draw, for several 269 
reasons (short duration of trial, poor tolerability of supplementation, inability of patients to 270 
complete the study). Also the recent Cochrane (19) review about EPA for treatment of cancer 271 
cachexia did not confirm or reject the use of EPA in clinical practice; the results of the systematic 272 
review suggest that there is little evidence of harm deriving from the use of EPA. On the contrary, 273 
other studies have reported that EPA + DHA, as in our research, or EPA alone, reduce weight loss 274 
in patients with advanced cancer (33, 40, 41). In the case of other studies (9, 17, 40-42) a 275 
comparison with this research is difficult, because of methodological differences (lung, pancreatic 276 
or gastrointestinal cancer, treated with pure EPA). 277 
A reduction of inflammatory parameter values found in the n-3 group versus the placebo group, 278 
although not always statistically significant, was observed. For example, CPR and IL-6 levels 279 
showed a significant difference between n-3 and placebo groups at T3 (p<0.05) and a progressive 280 
decrease during chemotherapy in the n-3 group, evidencing an anti-inflammatory action of n-3 281 
PUFAs. On the contrary, variations in TNFα were not significant, and those of PGE2 (expression of 282 
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pro-inflammatory factors) were statistically significant (p<0.05) from T0 to T2 and T3 in the n-3 283 
group, but not between the two groups. 284 
Some studies (10, 33, 43) have reported that n-3 PUFAs may suppress inflammatory cytokines in 285 
patients with advanced cancers; our data confirm this result . Van der Meij et al (43) recently 286 
published the results of a randomised, case-control, double-blind trial of 40 patients with stage III 287 
NSCLC, who received chemotherapy and radiotherapy, together with either supplements containing 288 
2 gr of EPA or isocaloric control supplements. After five weeks of treatment they observed that 289 
levels of inflammatory markers had decreased during chemotherapy and that IL-6 production was 290 
lower in the intervention group than in the control group. 291 
To evaluate the oxidative status throughout the period of the trial reported here, ROS and HNE 292 
levels were determined. Plasma ROS levels were higher in the placebo group than in the n-3 group 293 
at the later treatment times (p<0.05). HNE levels (expression of the injury from cellular oxidation) 294 
significantly (p<0.05) increased in the placebo group during the study, while they stabilized in the 295 
n-3 group; this demonstrates the cellular oxidative effect of chemotherapy drugs, and the probable 296 
protective action of EPA + DHA. The difference between the two groups at the end of the study 297 
was also statistical significant. 298 
Our data are encouraging with regard to the goals achieved, although the number of patients was 299 
limited: a statistically significant increase in body weight together with a reduction of inflammatory 300 
and oxidative parameters in the n-3 group confirm that the continual assumption of EPA + DHA 301 
showed an anti-inflammatory and anti-oxidative action, which might be considered a preliminary 302 
goal in anti-cachectic therapy. 303 
 304 
 305 
Conclusions 306 
 307 
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Although numerous studies have addressed this subject and there is great interest in scientific 308 
research concerning n-3 fatty acids, there is as yet little clinic proof to justify applying the results to 309 
cancer patients. 310 
In our randomised, double-blind study, despite the small number of patients, we analysed clinical, 311 
inflammatory and oxidative status during a period of 66 days, until the end of chemotherapy. 312 
From this we may conclude that: 313 
- fewer patients dropped-out than did from other studies; 314 
- compliance with the dieticians’ recommendations, and with the EPA and DHA assumption, 315 
were good; 316 
- body weight increased significantly in the n-3 group; 317 
- a significant reduction in inflammatory indexes and in oxidative status was observed. 318 
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TABLE 1 - Nutritional status and calorie and protein intakes at baseline and at study end (T0 and 446 
T3) 447 
  
n-3 group (n= 13) 
(M/F 8/5) 
 
SD 
Placebo group (n= 14) 
(M/F  11/3) 
 
SD 
 
Weight loss % 
 
T0 3.0  3.5 2.0  3.3 
Karnofsky 
Performance Status 
 
T0 80  10 80  10 
BMI (kg/m2) 
 
T0 26.19  6.98 25.25  3.92 
T3 27.65  7.02 25.58  4.43 
Calorie intake/day 
(Kjoule/Kg)(Kcal/d
ay)  
T0 8072.47 1990.56  
1596.3 
393,44
7371.46 1685.57  
1421.95 
169.32 
T3 
8840.08 
2160  
1147.7 
330.8 
7131.32 1730.29  
1016.10 
242.69 
Protein intake/day 
(g/day)  
T0 68.56  15.03 60.00  8.5 
T3 74.88  17.33 61.43  8.52 
Calorie intake/Kg 
(Kjoule /Kg) 
(K/Kg)  
T0 
119.31  
29.22  
26.85 
6.38 
110.63  
26.42  
23.64 
5.65 
T3 
120.48  
29.63  
26.69 
7 
109.32  
26.11  
17.08 
4.08 
Protein intake/Kg 
(g/kg)  
T0 1.02  0.29 0.94  0.24 
T3 1.04  0.32 0.94  0.16 
 448 
The weight loss percentage is related to the last three months, before the start of the study. 449 
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Figure legends 450 
 451 
FIGURE 1 – Study design 452 
 453 
FIGURE 2 – Comparison of weight changes (Kg) in the placebo and n-3 groups during the 454 
experimental time 455 
Data are expressed as means ± S.D. * “paired t test” p<0.05 T3 versus T0. 456 
(–▲–) placebo group, (–□–) n-3 group 457 
 458 
FIGURE 3 – Comparison of changes in EPA and DHA in plasma and in erythrocyte membrane 459 
content in the placebo and n-3 groups during the experimental time 460 
Data are expressed as means ± S.D. and are the percentage content of EPA in plasma (panel A) and 461 
erythrocyte membranes (panel B), and the percentage content of DHA in plasma (panel C) and 462 
erythrocyte membranes (panel D). 463 
*“paired t test” p<0.05 T1, T2, T3 versus T0. 464 
§ “unpaired t test” p<0.05 n-3 group versus placebo group. 465 
(–▲–) placebo group, (–□–) n-3 group 466 
 467 
FIGURE 4 – Comparison of changes in CPR, IL-6, PGE2 and TNF-α content in plasma in the 468 
placebo and n-3 groups during the experimental time 469 
Data are expressed as means ± S.D. and are the plasma content of CPR (panel A), IL-6 (panel B), 470 
and PGE2 (panel C). 471 
* “paired t test” p<0.05 T2, T3 versus T0. 472 
§ “unpaired t test” p<0.05 n-3 group versus placebo group. 473 
(–▲–) placebo group, (–□–) n-3 group 474 
 475 
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FIGURE 5 – Comparison of changes in HNE and ROS content in plasma in the placebo and n-3 476 
groups during the experimental time 477 
Data are expressed as means ± S.D. and are the plasma content of HNE (panel A) and ROS (panel 478 
B). 479 
* “paired t test” p<0.05 T3 versus T0. 480 
§ “unpaired t test” p<0.05 n-3 group versus placebo group. 481 
(–▲–) placebo group, (–□–) n-3 group 482 
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